<DOC>
	<DOC>NCT02799758</DOC>
	<brief_summary>The purpose of this study is to demonstrate the superior efficacy of NK-104-CR 8 mg daily compared to Livalo速 IR 4 mg daily on fasting serum low-density lipoprotein cholesterol (LDL-C) reduction and to evaluate the comparative safety of NK-104-CR 8 mg daily to Livalo速 IR 4 mg daily after long-term treatment</brief_summary>
	<brief_title>Efficacy &amp; Long-term Safety Comparison Study of NK-104-CR &amp; Livalo速 IR With Primary Hyperlipidemia or Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Male and female patients with primary hyperlipidemia or mixed dyslipidemia Patients for whom lipidlowering therapy is indicated according to NCEP ATPIII Patients who are na誰ve to statin or who are able to safely discontinue the use of all lipidlowering agents for 4 weeks before randomization and throughout study participation Homozygous familial hypercholesterolemia; Any conditions which may cause secondary dyslipidemia. Newly diagnosed or poorly controlled diabetes mellitus as defined by HbA1c &gt;9%</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>